---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-050525"
form_type: "8-K"
ticker: "LYRA"
cik: "0001327273"
company_name: "Lyra Therapeutics, Inc."
filed_at: "2024-04-30T23:59:59+00:00"
generated_at: "2026-06-03T04:11:19.912648+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lyra Therapeutics Q1 net loss $22.5M; ENLIGHTEN 1 Phase 3 results expected in May 2024

## Summary
- Cash $87.1M at March 31, 2024 vs $102.8M at Dec 31, 2023; cash runway into Q1 2025.
- Net loss $22.5M vs $16.3M in Q1 2023; R&D expense $18.2M (up $5.6M YoY).
- ENLIGHTEN 1 pivotal Phase 3 data for LYR-210 in CRS expected in May 2024.
- ENLIGHTEN 2 enrollment completion expected H2 2024; LYR-220 end-of-Phase 2 meeting with FDA anticipated H2 2024.
- BEACON Phase 2 data for LYR-220 to be presented at COSM on May 15, 2024.

## SEC filing metadata
- accession: 0000950170-24-050525
- form_type: 8-K
- ticker: LYRA
- cik: 0001327273
- company_name: Lyra Therapeutics, Inc.
- filed_at: 2024-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1327273/000095017024050525/0000950170-24-050525-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1327273/000095017024050525/lyra-20240430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-050525
- JSON: https://secwatch.observer/filing/0000950170-24-050525.json
- Plain text: https://secwatch.observer/filing/0000950170-24-050525.txt

## Key facts
- Earnings Releases
  Lyra Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income Net loss for the first quarter 2024 was $22.5 million compared to $16.3 million for the same period in 2023..
  - Period: first quarter ended March 31, 2024
  - Net income: Net loss for the first quarter 2024 was $22.5 million compared to $16.3 million for the same period in 2023.
  - Result: reported results
  source text: Net loss for the first quarter 2024 was $22.5 million compared to $16.3 million for the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1327273/000095017024050525/0000950170-24-050525-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.